---
schema_version: "secwatch.filing_event.v1"
accession: "0001534120-25-000022"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-12-02T23:59:59+00:00"
generated_at: "2026-05-16T15:42:23.612736+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Avalo posts updated investor presentation; no specific new data disclosed

## Summary
- Company filed 8-K announcing updated investor presentation posted on its website.
- Presentation is a corporate overview focused on IL-1β therapies pipeline.
- No financial results, trial data, or guidance changes included in the filing text.
- Presentation will be used in meetings with investors going forward.

## SEC filing metadata
- accession: 0001534120-25-000022
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000153412025000022/0001534120-25-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000153412025000022/avtx-20251202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534120-25-000022
- JSON: https://secwatch.observer/filing/0001534120-25-000022.json
- Plain text: https://secwatch.observer/filing/0001534120-25-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.